Status
Conditions
Treatments
About
The objective of this clinical trial is to determine whether long-term oral dosage of ribavirin delays development of symptomatic HIV disease in HIV antibody positive subjects who are completely asymptomatic (CDC classification group II), who have only the lymphadenopathy syndrome (CDC classification group III), or who have clinical symptoms but not severe HIV disease as defined by CDC classification, and whether the dosage regimen is safe and tolerable in these subjects.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Positive plasma p24 antigen.
Prior Medication:
Excluded within 4 weeks of start of screening tests:
HIV infection group II (CDC), asymptomatic HIV infection.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal